Recap of Rexpo 2024 on AI and Repurposing
![](https://s3.kantify.dev/kantify-website/insight/Screenshot_2024-07-11_122811.jpg?AWSAccessKeyId=kantify.website.cicd&Signature=cdV6pt8X6wQ%2FtfLgDzTr0RqKBQo%3D&Expires=1725765284)
Rexpo 2024, the 3rd international conference on systems medicine, AI & drug repurposing, took place on 3-5 July in München, Germany.
The work of Kantify was highlighted in 2 presentations:
AI for target and small molecule prediction for rare cancers
Kantify's CTO Nik Subramanian presented some of our novel findings on using Artificial Intelligence to find repurposed drugs which are effective on rare cancers.
In his presentation "AI and phenotypic screens lead to the discovery of common treatments for multiple distinct rare diseases with shared commonalities - a use case and what's next", Nik demonstrated how we use Kantify's AI platform Sapian to find novel therapeutics targets and drugs. He shared our extremely promising results on some rare cancers with no cures, where in less than 5 months we have successfully predicted and validated novel targets and drugs.
AI for target and small molecule prediction for rare neuromuscular disorders.
Xavier Nissan, Research Director at i-Stem, presented our common Horizon Europe project DREAMS, funded by the European Commission, of which he is the Coordinator. Kantify is co-coordinator as, for the AI pillar, the project relies on Kantify's AI platform for target and small molecule prediction, Sapian.
In DREAMS, we combine AI and induced Pluripotent Stem Cells (iPSCs) to discover drugs which are effective on several rare neuromuscular disorders. DREAMS is an ambitious project which relies on initial validations from the long standing collaboration between I-Stem (the French reference for iPSCs) and Kantify (with its novel AI platform for drug discovery Sapian). DREAMS gathers a large consortium of excellent research institutes, companies, and the patient organization AFM-Téléthon.
Next steps
With our initial validations, we are looking forward to help rare disease patients, biotechs and pharma, to accelerate the repurposing of drugs for indication where patients are waiting for a therapy.
Learn more
Would you like to learn more or consider a partnership related to the above projects? Reach out through our contact form.